The U.S. Food and Drug Administration (FDA) has announced a major initiative to hire over 1,000 new scientists to accelerate its drug review process.
This hiring spree is not simply about expansion; it's an urgent effort to rebuild. In 2025, the FDA's key drug review centers, CDER and CBER, experienced a sharp decline in staff, losing over 1,300 employees combined. This created a significant operational gap, threatening the agency's ability to meet its PDUFA performance goals, which are commitments to review new drugs within specific timelines.
So, what led to this critical moment? The situation developed through a clear causal chain. First, the foundation was the severe staff shortage itself. Public data released by the FDA in early February 2026 confirmed the continued staff losses, while government watchdog reports from the GAO had been flagging retention issues for over a year. This created undeniable pressure to act.
Second, this staffing crisis collided with a strong policy push from FDA leadership to